Compare BOXL & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOXL | VIVS |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.9M |
| IPO Year | 2015 | N/A |
| Metric | BOXL | VIVS |
|---|---|---|
| Price | $0.77 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 68.1K | 37.0K |
| Earning Date | 04-16-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,743,612.00 | N/A |
| Revenue This Year | $2.70 | $42.38 |
| Revenue Next Year | $5.00 | $15.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.37 | N/A |
| 52 Week Low | $0.50 | $1.13 |
| 52 Week High | $10.15 | $5.30 |
| Indicator | BOXL | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | 30.77 |
| Support Level | $0.70 | N/A |
| Resistance Level | $0.95 | $1.38 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 23.53 | 6.77 |
Boxlight Corp is a technology company that develops, sells, and services interactive solutions predominantly for the education market but also for the corporate and government sectors. The company currently designs, produces, and distributes interactive technologies, including interactive and non-interactive flat panel displays, LED video walls, media players, classroom audio and campus communication, cameras, and other peripherals for the education market and non-interactive solutions, including flat-panels, LED video walls, and digital signage for the enterprise market. It has three reportable segments - Europe, Middle East and Africa (EMEA), and North and Central America (Americas). The majority of revenue is derived from the sale of education technology products in the EMEA segment.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.